Feb 12 (Reuters) - AnaptysBio ANAB.O:
ANAPTYS ANNOUNCES ROSNILIMAB ACHIEVED POSITIVE RESULTS IN RA PHASE 2B TRIAL AND HIGHEST EVER REPORTED CDAI LDA RESPONSE OVER 6 MONTHS
ANAPTYSBIO INC - ROSINILIMAB SAFE AND WELL TOLERATED WITH SIMILAR ADVERSE EVENT RATES VERSUS PLACEBO
ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL SIGNIFICANCE ON KEY SECONDARY ENDPOINTS AT WEEK 12
ANAPTYSBIO INC - ROSINILIMAB ACHIEVES STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 12
ANAPTYSBIO INC - TOP-LINE WEEK 12 PHASE 2 ULCERATIVE COLITIS DATA FOR ROSNILIMAB EXPECTED IN Q4 2025
Source text: ID:nGNXc9Q9Gv
Further company coverage: ANAB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.